Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Current Deferred Revenue (2022 - 2025)

AVITA Medical (RCEL) has disclosed Current Deferred Revenue for 4 consecutive years, with $323000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 9.52% year-over-year to $323000.0, compared with a TTM value of $323000.0 through Dec 2025, down 9.52%, and an annual FY2025 reading of $323000.0, down 9.52% over the prior year.
  • Current Deferred Revenue was $323000.0 for Q4 2025 at AVITA Medical, down from $331000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $698000.0 in Q4 2022 and bottomed at $205000.0 in Q2 2024.
  • Average Current Deferred Revenue over 4 years is $414000.0, with a median of $365000.0 recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 63.2% in 2024, then skyrocketed 65.85% in 2025.
  • Year by year, Current Deferred Revenue stood at $698000.0 in 2022, then tumbled by 44.13% to $390000.0 in 2023, then fell by 8.46% to $357000.0 in 2024, then decreased by 9.52% to $323000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for RCEL at $323000.0 in Q4 2025, $331000.0 in Q3 2025, and $340000.0 in Q2 2025.